Laborie Medical Technologies, Inc. ("LABORIE"), based in Toronto, Ontario, has completed its acquisition of BUCK Elektromedizin GmbH and BUCKmeditec GmbH & Co. Bad Rappenaeau, Germany based BUCK develops and distributes innovative and advanced biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of urinary and fecal incontinence.
"Both LABORIE and BUCK have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products," stated Brian Ellacott, LABORIE President and CEO. "By combining existing product lines with BUCK's extensive customer base, we can provide a greater breadth of innovative products and services to enable German urologists to deliver better care to their patients."
LABORIE's acquisition of BUCK further extends its market leadership in Pelvic Muscle Rehabilitation. The acquisition also expands LABORIE's presence in the German market by adding 15 in-country sales representatives that will market the full range of both LABORIE and BUCK products.
BUCK managing director Franz Dettling said, "We are excited to partner with a global leader in urology who will help us expand the breadth of our offering to German urologists as well as help provide access to our unique pelvic therapy offerings around the world."
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels